Recent News

• 11.25.2025 - Unicycive Therapeutics to Participate in Upcoming Investor Events in December
• 11.12.2025 - Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
• 11.03.2025 - Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
• 10.30.2025 - Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference
• 10.28.2025 - Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
• 08.26.2025 - Unicycive Therapeutics to Participate in Upcoming Investor Events in September
• 08.18.2025 - Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

Recent Filings

• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 11.14.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - 8-K Current report
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]